Home  /  Investors   /  Press releases

Press releases

Here you will find all press releases from XVIVO.

Showing 1 to 30 out of 33 posts.
30 Dec, 2022
Increased number of shares and votes in XVIVO Perfusion AB (publ)
30 Nov, 2022
Christoffer Rosenblad appointed as CEO of XVIVO
30 Nov, 2022
XVIVO completes the acquisition of the machine and perfusion business from Avionord S.r.l.
28 Nov, 2022
XVIVO strengthens its executive management team by appointing Lena Hagman to Chief Operating Officer, COO
24 Nov, 2022
Positive results presented from the Australian & New Zealand heart preservation study
27 Oct, 2022
Interim Report January – September 2022
21 Oct, 2022
Conference call on Interim Report
30 Sep, 2022
Nomination committee of XVIVO Perfusion AB (publ)
27 Sep, 2022
XVIVO Perfusion’s CEO Dag Andersson has passed away
21 Sep, 2022
XVIVO presents strategy for 2023-2027 at its Capital Markets Day
20 Sep, 2022
XVIVO granted Breakthrough Device Designation from the FDA for the Liver Assist device
24 Aug, 2022
XVIVO Capital Markets Day 2022
1 Aug, 2022
XVIVO enters into an agreement to acquire its Italian distributor – securing a unique business model
13 Jul, 2022
XVIVO presents interim report january-june 2022
30 Jun, 2022
Change in number of shares and votes in XVIVO Perfusion
29 Jun, 2022
Conference call on Interim Report
19 May, 2022
CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologies
18 May, 2022
XVIVO to advance their digital transformation journey in partnership with the world-leading Cleveland Clinic to increase the number of successful lung transplants
12 May, 2022
Reimbursement established for lung and liver transplant in the Netherlands based on results from clinical trials with XVIVO’s leading technologies
4 May, 2022
XVIVO has executed agreements with leading US hospitals and delivered the first Kidney Assist Transport devices
27 Apr, 2022
XVIVO submits an IDE application to US FDA for its innovative heart technology – a significant milestone
26 Apr, 2022
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
25 Apr, 2022
XVIVO presents interim report January-March 2022
13 Apr, 2022
Conference call on Interim Report
4 Apr, 2022
Annual report 2021
24 Mar, 2022
Notice to attend the annual general meeting in XVIVO Perfusion AB (publ)
23 Mar, 2022
XVIVO obtains its first certificate under EU Medical Device Regulation (MDR) for Kidney Assist Transport
2 Feb, 2022
XVIVO gains regulatory approval in China for PERFADEX® Plus – the global gold standard for lung preservation
27 Jan, 2022
XVIVO presents Report on Operations 2021
21 Jan, 2022
XVIVO’s Kidney Assist Transport receives 510(k) clearance by US FDA, which is XVIVO’s first regulatory cleared product for abdominal transplantation in the US

Fill out the form to watch the video